Low dose, high dose, or no dose: Better prescribing of cholinesterase inhibitors for Alzheimer's disease

International Psychogeriatrics

Volumn 25, Issue 4, 2013, Pages 511-515

  Ritchie, C W ^a,b   Zhinchin, G ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; CLINICAL PRACTICE; COGNITION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FOLLOW UP; HUMAN; LONG TERM CARE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROTOXICITY; PRESCRIPTION; PRESYNAPTIC INHIBITION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPREGULATION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; HUMANS; MAXIMUM TOLERATED DOSE; PHENYLCARBAMATES; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 84874184254     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610212002414     Document Type: Review

References (23)

1. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews, 25, CD005693
2. Bond, C. E. et al. (2006). Astroglia up-regulate transcription and secretion of "readthrough" acetylcholinesterase following oxidative stress. European Journal of Neuroscience, 24, 381-386 (Pubitemid 44100330)
3. Cummings, J. L. and Back, C. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. American Journal of Geriatric Psychiatry, 6 (2 Suppl. 1), S64-S78
4. Cummings, J. et al. (2012). Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 33, 341-353
5. Darreh-Shori, E., Hellström-Lindahl, C., Flores-Flores, Z. Z., Guan,H., Soreq, A. and Nordberg, A. (2004). Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. Journal of Neurochemistry, 88, 1102-1113 (Pubitemid 38280678)
6. de Oliveira, P., Gomes, A. Q., Pacheco, T. R., de Almeida, V. V., Saldanha, C. and Calado, A. (2012). Cell-specific regulation of acetylcholinesterase expression under inflammatory conditions. Clinical Hemorheology and Microcirculation, 51, 129-137
7. Doody, R. S., Corey-Bloom, J., Zhang, R., Li, H., Leni, J. and Schindler, R. (2008). Safety and tolerability of donepezil at dozes up to 20 mg/day. Results from a pilot study in patients with Alzheimer's disease. Drugs and Aging, 25, 163-174 (Pubitemid 351225820)
8. Doody, R. S. et al. (2009). Donepezil treatment of patients with MCI: A 48-week randomized, placebo-controlled trial. Neurology, 72, 1555-1561
9. Farlow, M. (2002). A clinical overview of cholinesterase inhibitors in Alzheimer's disease. International Psychogeriatrics, 14, 93-126 (Pubitemid 36206093)
10. Farlow, M. R. et al. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clinical Therapeutics, 32, 1234-1251
11. García-Ayllón, M. S., Silveyra, M. X., Andreasen, N., Brimijoin, S., Blennow, K. and Sáez-Valero, J. (2007). Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. Journal of Neurochemistry, 101, 1701-1711 (Pubitemid 46848854)
12. Howard, R. et al. (2012). Donepezil and memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 366, 893-903
13. Minger, S. L. et al. (2000). Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology, 55, 1460-1467
14. Nagele, R. G., D'Andrea, M. R., Anderson, W. J. and Wang, H. Y. (2002). Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience, 110, 199-211 (Pubitemid 34214939)
15. Parnetti, L. et al. (2011). Changes in CSF acetyl-and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. Acta Neurologica Scandinavica 124, 122-129
16. Prickaerts, J. et al. (2012). EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology, 62, 1099-110
17. Ritchie, C. W., Ames, D., Clayton, T. and Lai, R. (2004). Metaanalysis of randomised trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. The American Journal of Geriatric Psychiatry, 12, 358-369 (Pubitemid 38878856)
18. Rogers, S. L., Doody, R. S., Mohs, R. C., Friedhoff, L. T. (The Donepezil Study Group) (1998a). Donepezil improves cognition and global functioning in Alzheimer's disease: A 15-week, double-blind, placebo controlled study. Archives of Internal Medicine, 158, 1021-1031
19. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T. (The Donepezil Study Group) (1998b). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer disease. Neurology, 50, 136-145
20. Schneider, L. S. (2012). Could cholinesterase inhibitors be harmful over the long term? International Psychogeriatrics, 24, 171-174
21. Sona, A. et al. (2012). Predictors of rapid cognitive decline in Alzheimer's disease: Results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. International Psychogeriatrics, 24, 197-204
22. Trojanowski, J. Q. et al. (2010). Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's and Dementia, 6, 230-238
23. Winblad, B. et al. (2008). Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 70, 2024-2035